BCM
CTMX icon

Blume Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Blume Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-900
Closed -$14K – 228
2018
Q4 		$14K Buy
+900
New +$13.4K 0.01% 177

Other funds holding CTMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Blume Capital Management's CTMX Position: Q1 2019 in Review

Blume Capital Management sold out of CytomX Therapeutics (CTMX) in Q1 2019, closing a stake of 900 shares — an estimated $14K sold.

Blume Capital Management first reported a position in CTMX in Q4 2018 and held it in 1 quarter. The position peaked at $14K in Q4 2018. 113 funds tracked by Wall St. Rank hold CTMX as of Q1 2019.

  • Blume Capital Management reported no remaining CytomX Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Blume Capital Management sold 900 CytomX Therapeutics shares in Q1 2019, an estimated $14K.
  • Blume Capital Management first reported a position in CytomX Therapeutics in Q4 2018 and held it in 1 quarter.
  • Blume Capital Management's CytomX Therapeutics position peaked at $14K in Q4 2018.
  • 113 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2019.

Based on Blume Capital Management's 13F filing for Q1 2019, filed 6 May 2019.